title: Can Burkholderia cepacia complex be eradicated with nebulised amiloride and TOBI?
authors.forename: R
authors.initials: R
authors.lastname: Ball
authors.forename: K G
authors.initials: KG
authors.lastname: Brownlee
authors.forename: A J A
authors.initials: AJ
authors.lastname: Duff
authors.forename: M
authors.initials: M
authors.lastname: Denton
authors.forename: S P
authors.initials: SP
authors.lastname: Conway
authors.forename: T W R
authors.initials: TW
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D000584:Amiloride / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D019121:Burkholderia Infections / Q000150:complications* / Q000188:drug therapy*; D042602:Burkholderia cepacia complex / Q000187:drug effects*; D002648:Child; D003550:Cystic Fibrosis / Q000382:microbiology*; D004359:Drug Therapy, Combination; D006801:Humans; D009330:Nebulizers and Vaporizers; D026941:Sodium Channel Blockers / Q000008:administration & dosage; D014031:Tobramycin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D026941:Sodium Channel Blockers; D000584:Amiloride; D014031:Tobramycin